The biopharmaceutical industry is a strategic emerging industry that is related to the national economy, people's livelihood, and national security. In recent years, China's biopharmaceutical industry has entered a "fast lane" of development, with innovative achievements represented by domestically produced innovative drugs constantly emerging. In the future, what further efforts are needed for the innovative development of China's biopharmaceutical industry? In this regard, this newspaper conducted an interview. On April 3rd, at the Zhongguancun Life Science Park in Changping District, Beijing, the "Beijing Pharmaceutical and Medical Device Innovation Service Station" was unveiled and settled. The innovation service station will provide one-stop services for biopharmaceutical enterprises, establish customized consultation platforms, resource sharing platforms, and personnel training platforms, achieve pre approval and service advancement, and promote the transformation and rapid listing of innovative drug and medical device research and development achievements. Measures like this to safeguard the development of the biopharmaceutical industry have been increasingly implemented in Zhongguancun Life Science Park in recent years. After more than 20 years of development and accumulation, the park has gathered more than 600 innovative pharmaceutical enterprises, becoming an innovation engine for the development of the pharmaceutical and health industry in Beijing and even the whole country. Turn your attention to Shanghai again. On April 10th, the theme conference for the 20th anniversary of the establishment of Zhangjiang Science City Shanghai International Medical Park was held. According to reports, the park has attracted over 1000 industry renowned institutions and enterprises to settle down. In the future, we will further strengthen the core construction of innovative policy sources here; Strengthen the layout of cutting-edge fields and focus on major unmet needs in clinical applications; Further strengthen the construction of platforms and service systems. This year, the Zhangjiang Gene Island with a total construction area of 160000 square meters will also be newly completed, attracting more enterprises with innovative technologies such as cells and genes to settle down. Also in the Yangtze River Delta region, the 7th China Pharmaceutical Innovation and Investment Conference was recently held in Suzhou, Jiangsu Province. Currently, the biopharmaceutical industry has become the "number one industry" vigorously cultivated by Suzhou City. In southwest China, Chengdu, Sichuan Province, will print and distribute the "14th Five Year Plan" biobased economy Development Plan of Chengdu in 2022. It is proposed that during the "14th Five Year Plan" period, the average annual growth rate of the biobased economy will remain at about 15%. By 2025, the total output value of the biobased economy will reach 1.2 trillion yuan, forming a bio industry cluster with international competitiveness for innovative drugs and high-end medical devices. From north to south and from east to west, the biopharmaceutical industry is thriving in various regions. The Beijing Tianjin Hebei region, the Yangtze River Delta, the Guangdong Hong Kong Macao Greater Bay Area, and the Chengdu Chongqing dual city economic circle have become innovative highlands for the national biopharmaceutical industry; Multiple provinces, regions, and cities have listed pharmaceutical manufacturing and biotechnology industries as advantageous or prioritized industries for development. In the interview, several industry insiders stated that the rise of China's biopharmaceutical industry is inseparable from the continuous support of relevant policies in recent years. In August 2015, the State Council issued the "Opinions on Reforming the Review and Approval System for Pharmaceutical and Medical Devices", marking the beginning of the reform of China's pharmaceutical and medical device review and approval system. Nowadays, drugs and medical devices have basically been reviewed and approved according to legal time limits. In 2022, 1279 drugs were approved for marketing throughout the year, including 18 innovative drugs; Approved 2500 first-time registered medical device products, including 55 innovative medical devices. Over the past five years, there has been a total of 1